Ken Griffin Sangamo Therapeutics, Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$0.36 - $0.65 $1,476 - $2,665	-4,100 Reduced 21.13%	15,300 $5,000
Q1 2024 May 15, 2024	SELL	$0.42 - $1.38 $17,892 - $58,787	-42,600 Reduced 68.71%	19,400 $12,000
Q4 2023 Feb 14, 2024	SELL	$0.3 - $0.63 $750 - $1,575	-2,500 Reduced 3.88%	62,000 $33,000
Q3 2023 Nov 14, 2023	BUY	$0.58 - $1.47 $4,234 - $10,731	7,300 Added 12.76%	64,500 $38,000
Q1 2023 May 15, 2023	SELL	$1.66 - $3.67 $59,926 - $132,487	-36,100 Reduced 38.69%	57,200 $100,000
Q4 2022 Feb 14, 2023	SELL	$2.77 - $5.07 $41,550 - $76,050	-15,000 Reduced 13.85%	93,300 $292,000
Q3 2022 Nov 14, 2022	BUY	$4.27 - $6.39 $24,765 - $37,062	5,800 Added 5.66%	108,300 $531,000

135

86.5M

35.9K

156K

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $319M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.